CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY/(DEFICIT) - USD ($) $ in Thousands	Total	Common Shares	Additional Paid in Capital	Deficit Accumulated
Balance, Beginning of Period (in shares) at Dec. 31, 2013		90,182,115
Balance, Beginning of Period at Dec. 31, 2013	$ 55,348	$ 10	$ 226,515	$ (171,177)
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity “at-the-market” sales agreement (in shares)		6,417,650
Common stock issued pursuant to a controlled equity “at-the-market” sales agreement	30,700	$ 1	30,699
Fees and expenses related to controlled equity sales	(846)		(846)
Stock based compensation expense	4,722		4,722
Common stock issued in connection with exercise of stock options (in shares)		9,999
Common stock issued in connection with exercise of stock options	36		36
Private placement of ContraVir common stock	3,224		3,224
Fees and expenses associated with ContraVir Private Placement	(15)		(15)
Fair value of ContraVir warrants issued in connection with private placement	(880)		(880)
Noncontrolling interest of ContraVir	(1,622)
Distribution of ContraVir common stock to Synergy shareholders	(1,740)		(1,740)
Elimination of noncontrolling interest of ContraVir upon distribution	1,622
Net loss for the period	(95,708)			(95,708)
Balance, End of Period (in shares) at Dec. 31, 2014		96,609,764
Balance, End of Period at Dec. 31, 2014	(5,159)	$ 11	261,715	(266,885)
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity “at-the-market” sales agreement (in shares)		3,435,998
Common stock issued pursuant to a controlled equity “at-the-market” sales agreement	14,672	$ 0	14,672
Fees and expenses related to controlled equity sales	(404)		(404)
Stock based compensation expense	9,724		9,724
Common stock issued in connection with exercise of stock options (in shares)		269,720
Common stock issued in connection with exercise of stock options	1,142		1,142
Common stock issued in connection with exercise of warrants (in shares)		189,412
Common stock issued in connection with exercise of warrants	1,012	$ 0	1,012
Shares issued in connection with conversion of Senior Convertible Debentures (in shares)		13,179,712
Shares issued in connection with conversion of Senior Convertible Debentures	40,989	$ 0	40,989
Change in fair value of warrants due to expiration of certain warrants	244		244
Stock issues in exchange for certain intellectual property (in shares)		10,000
Stock issues in exchange for certain intellectual property	67		67
Net loss for the period	$ (117,500)			(117,500)
Balance, End of Period (in shares) at Dec. 31, 2015	113,694,606	113,694,606
Balance, End of Period at Dec. 31, 2015	$ (55,213)	$ 11	329,161	(384,385)
Increase (Decrease) in Stockholders' Equity
Stock based compensation expense	12,575		12,575
Common stock issued in connection with exercise of stock options (in shares)		70,185
Common stock issued in connection with exercise of stock options	222		222
Common stock issued in connection with exercise of warrants (in shares)		2,430,656
Common stock issued in connection with exercise of warrants	11,331	$ 1	11,330
Shares issued in connection with conversion of Senior Convertible Debentures (in shares)		44,432,408
Shares issued in connection with conversion of Senior Convertible Debentures	137,941	$ 4	137,937
Debt conversion expense (in shares)		12,161,671
Debt conversion expense	40,158	$ 1	40,157
Transaction fees on Note conversions	(711)		(711)
Common stock issued in registered direct offering net of issuance costs (in shares)		29,948,334
Common stock issued in registered direct offering, net of issuance costs	89,845	$ 3	89,842
Net loss for the period	$ (198,607)			(198,607)
Balance, End of Period (in shares) at Dec. 31, 2016	202,737,860	202,737,860
Balance, End of Period at Dec. 31, 2016	$ 37,541	$ 20	$ 620,513	$ (582,992)